CANSINOBIO (06185) announced its financial results for the three months ended March 31, 2026. The company reported an operating revenue of 190 million yuan, representing a year-on-year increase of 38.73%. However, the net loss attributable to shareholders reached 40.4243 million yuan, marking a significant expansion of 250.13% compared to the same period last year. The basic loss per share was 0.16 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments